Swiss National Bank Roivant Sciences Ltd. Transaction History

Swiss National Bank

$146 Billion
Q4 2024

A detailed history of Swiss National Bank transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Swiss National Bank holds 727,246 shares of ROIV stock, worth $7.75 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

727,246

Previous 721,046 0.86%

Holding current value

$7.75 Million

Previous $8.32 Million 3.4%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$11.16 - $12.71 $69,192 - $78,802	6,200 Added 0.86%	727,246 $8.6 Million
Q3 2024 Nov 07, 2024	BUY	$10.17 - $12.5 $70,173 - $86,250	6,900 Added 0.97%	721,046 $8.32 Million
Q2 2024 Aug 08, 2024	BUY	$10.36 - $11.74 $1.64 Million - $1.86 Million	158,600 Added 28.55%	714,146 $7.55 Million
Q1 2024 May 07, 2024	BUY	$9.87 - $11.8 $86,856 - $103,840	8,800 Added 1.61%	555,546 $5.86 Million
Q4 2023 Feb 06, 2024	BUY	$8.38 - $11.58 $343,580 - $474,780	41,000 Added 8.11%	546,746 $6.14 Million
Q3 2023 Nov 08, 2023	SELL	$9.76 - $13.19 $2.32 Million - $3.13 Million	-237,300 Reduced 31.94%	505,746 $5.91 Million
Q2 2023 Aug 09, 2023	BUY	$7.09 - $10.08 $828,112 - $1.18 Million	116,800 Added 18.65%	743,046 $7.49 Million
Q1 2023 May 10, 2023	SELL	$6.92 - $9.98 $374,372 - $539,918	-54,100 Reduced 7.95%	626,246 $4.62 Million
Q4 2022 Feb 08, 2023	BUY	$3.36 - $7.99 $95,088 - $226,117	28,300 Added 4.34%	680,346 $5.44 Million
Q2 2022 Aug 09, 2022	BUY	$2.81 - $4.84 $1.83 Million - $3.16 Million	652,046 New	652,046 $2.65 Million

Others Institutions Holding ROIV

# of Institutions

332

Shares Held

505M

Call Options Held

573K

Put Options Held

739K

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $7.51B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Roivant Sciences Ltd. Transaction History